MNPR
Monopar Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$358.77M
P/E Ratio
—
EPS
$-1.85
Beta
1.67
52W High
$105.00
52W Low
$28.40
50-Day MA
$58.30
200-Day MA
$61.03
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -14.20% |
| Return on Assets | -10.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $20.59 |
| Price-to-Book | 2.68 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $6.69M |
| Float | $4.40M |
| % Insiders | 23.69% |
| % Institutions | 83.18% |
Analyst Ratings
Consensus ($112.79 target)
4
Strong Buy10
BuyData last updated: 4/8/2026